{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:20:21Z","timestamp":1790619621182,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Drug resistance in tuberculosis is exacerbating the threat this disease is posing to human beings. Antibiotics that were once effective against the causative agent, <jats:italic>Mycobacterium tuberculosis<\/jats:italic> (Mtb), are now no longer usable against multi- and extensively drug-resistant strains of this pathogen. To address this issue, new drug combinations and novel methods for targeted drug delivery could be of considerable value. In addition, studies have shown that the use of the antidepressant drug fluoxetine, a serotonin reuptake inhibitor, can be useful in the treatment of infectious diseases, including bacterial infections. In this study, an isoniazid and fluoxetine-conjugated multi-walled carbon nanotube nanofluid were designed to increase drug delivery efficiency alongside eliminating drug resistance in vitro. The prepared nanofluid was tested against Mtb. Expression levels of <jats:italic>inhA<\/jats:italic> and <jats:italic>katG<\/jats:italic> mRNAs were detected by Real-time PCR. ELISA was applied to measure levels of cytokine secretion (TNF-\u03b1, and IL-6) from infected macrophages treated with the nano delivery system. The results showed that these nano-drug delivery systems are effective for fluoxetine at far lower doses than for free drugs. Fluoxetine also has an additive effect on the effect of isoniazid, and their concomitant use in the delivery system can have significant effects in treating infection of all clinical strains of Mtb. In addition, it was found that the expression of isoniazid resistance genes, including <jats:italic>inhA, katG<\/jats:italic>, and the secretion of cytokines TNF\u03b1 and IL6 under the influence of this drug delivery system is well regulated. It was shown that the drug conjugation can improve the antibacterial activity of them in all strains and these two drugs have an additive effect on each other both in free and conjugated forms. This nano-drug delivery method combined with host targeted molecules could be a game-changer in the development of a new generation of antibiotics that have high therapeutic efficiencies, low side effects, and the potential to overcome the problem of drug resistance.<\/jats:p>","DOI":"10.1038\/s41598-022-13682-4","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T12:09:25Z","timestamp":1654862965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["An effective nano drug delivery and combination therapy for the treatment of Tuberculosis"],"prefix":"10.1038","volume":"12","author":[{"given":"Mojgan","family":"Sheikhpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Delorme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alibakhsh","family":"Kasaeian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Amiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Masoumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Sadeghinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayereh","family":"Ebrahimzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobina","family":"Maleki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahin","family":"Pourazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"13682_CR1","unstructured":"WHO. Global Tuberculosis Report. 2020. (2020)."},{"key":"13682_CR2","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1039\/C9MD00057G","volume":"10","author":"A Mabhula","year":"2019","unstructured":"Mabhula, A. & Singh, V. Drug-resistance in Mycobacterium tuberculosis: where we stand. MedChemComm 10, 1342\u20131360 (2019).","journal-title":"MedChemComm"},{"key":"13682_CR3","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.2147\/IJN.S34996","volume":"7","author":"B Saifullah","year":"2012","unstructured":"Saifullah, B., Hussein, M. Z. B. & Al Ali, S. H. H. Controlled-release approaches towards the chemotherapy of tuberculosis. Int. J. Nanomed. 7, 5451 (2012).","journal-title":"Int. J. Nanomed."},{"key":"13682_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.taap.2008.01.002","volume":"229","author":"S Tafazoli","year":"2008","unstructured":"Tafazoli, S., Mashregi, M. & O\u2019Brien, P. J. Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model. Toxicol. Appl. Pharmacol. 229, 94\u2013101 (2008).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"13682_CR5","first-page":"4749","volume":"9","author":"B Saifullah","year":"2014","unstructured":"Saifullah, B. et al. Development of a biocompatible nanodelivery system for tuberculosis drugs based on isoniazid-Mg\/Al layered double hydroxide. Int. J. Nanomed. 9, 4749 (2014).","journal-title":"Int. J. Nanomed."},{"key":"13682_CR6","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.tube.2019.04.012","volume":"116s","author":"ER Erwin","year":"2019","unstructured":"Erwin, E. R., Addison, A. P., John, S. F., Olaleye, O. A. & Rosell, R. C. Pharmacokinetics of isoniazid: The good, the bad, and the alternatives. Tuberculosis (Edinburgh, Scotland) 116s, S66\u2013S70. https:\/\/doi.org\/10.1016\/j.tube.2019.04.012 (2019).","journal-title":"Tuberculosis (Edinburgh, Scotland)"},{"key":"13682_CR7","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1183\/09031936.96.09102026","volume":"9","author":"T Schaberg","year":"1996","unstructured":"Schaberg, T., Rebhan, K. & Lode, H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur. Respir. J. 9, 2026\u20132030 (1996).","journal-title":"Eur. Respir. J."},{"key":"13682_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/358591a0","volume":"358","author":"Y Zhang","year":"1992","unstructured":"Zhang, Y., Heym, B., Allen, B., Young, D. & Cole, S. The catalase: Peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358, 591\u2013593 (1992).","journal-title":"Nature"},{"key":"13682_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.8284673","volume":"263","author":"A Banerjee","year":"1994","unstructured":"Banerjee, A. et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263, 227\u2013230 (1994).","journal-title":"Science"},{"key":"13682_CR10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/infdis\/173.1.196","volume":"173","author":"JM Musser","year":"1996","unstructured":"Musser, J. M. et al. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and-susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: Restricted array of mutations associated with drug resistance. J. Infect. Dis. 173, 196\u2013202 (1996).","journal-title":"J. Infect. Dis."},{"key":"13682_CR11","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1086\/515362%JTheJournalofInfectiousDiseases","volume":"178","author":"LA Basso","year":"1998","unstructured":"Basso, L. A., Zheng, R., Musser, J. M., Jacobs, W. R. Jr. & Blanchard, J. S. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: Enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J. Infect. Dis. 178, 769\u2013775. https:\/\/doi.org\/10.1086\/515362%JTheJournalofInfectiousDiseases (1998).","journal-title":"J. Infect. Dis."},{"key":"13682_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.mimet.2005.03.002","volume":"63","author":"YK Park","year":"2005","unstructured":"Park, Y. K. et al. Comparison of drug resistance genotypes between Beijing and non-Beijing family strains of Mycobacterium tuberculosis in Korea. J. Microbiol. Methods 63, 165\u2013172 (2005).","journal-title":"J. Microbiol. Methods"},{"key":"13682_CR13","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1128\/AAC.00964-09","volume":"54","author":"T Luo","year":"2010","unstructured":"Luo, T. et al. Selection of mutations to detect multidrug-resistant Mycobacterium tuberculosis strains in Shanghai, China. Antimicrob. Agents Chemother. 54, 1075\u20131081 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"13682_CR14","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1128\/AAC.41.7.1601","volume":"41","author":"WH Haas","year":"1997","unstructured":"Haas, W. H. et al. Molecular analysis of katG gene mutations in strains of Mycobacterium tuberculosis complex from Africa. Antimicrob. Agents Chemother. 41, 1601\u20131603 (1997).","journal-title":"Antimicrob. Agents Chemother."},{"key":"13682_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1089\/mdr.2008.0842","volume":"14","author":"F Doustdar","year":"2008","unstructured":"Doustdar, F., Khosravi, A. D., Farnia, P., Masjedi, M. R. & Velayati, A. A. Molecular analysis of isoniazid resistance in different genotypes of Mycobacterium tuberculosis isolates from Iran. Microb. Drug Resist. 14, 273\u2013279 (2008).","journal-title":"Microb. Drug Resist."},{"key":"13682_CR16","first-page":"57","volume":"16","author":"AD Khosravi","year":"2012","unstructured":"Khosravi, A. D., Goodarzi, H. & Alavi, S. M. Detection of genomic mutations in katG, inhA and rpoB genes of Mycobacterium tuberculosis isolates using polymerase chain reaction and multiplex allele-specific polymerase chain reaction. Braz. J. Infect. Dis. 16, 57\u201362 (2012).","journal-title":"Braz. J. Infect. Dis."},{"key":"13682_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0924-8579(99)00154-5","volume":"14","author":"JL Munoz-Bellido","year":"2000","unstructured":"Munoz-Bellido, J. L., Munoz-Criado, S. & Garc\u0131a-Rodr\u0131guez, J. A. Antimicrobial activity of psychotropic drugs: Selective serotonin reuptake inhibitors. Int. J. Antimicrob. Agents 14, 177\u2013180 (2000).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"13682_CR18","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.micpath.2018.07.040","volume":"123","author":"AK de Sousa","year":"2018","unstructured":"de Sousa, A. K. et al. New roles of fluoxetine in pharmacology: Antibacterial effect and modulation of antibiotic activity. Microb. Pathog. 123, 368\u2013371 (2018).","journal-title":"Microb. Pathog."},{"key":"13682_CR19","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2147\/TCRM.S262936","volume":"16","author":"M Sheikhpour","year":"2020","unstructured":"Sheikhpour, M. The current recommended drugs and strategies for the treatment of coronavirus disease (COVID-19). Ther. Clin. Risk Manag. 16, 933 (2020).","journal-title":"Ther. Clin. Risk Manag."},{"key":"13682_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2174\/1570159X12666140828221720","volume":"12","author":"L Peng","year":"2014","unstructured":"Peng, L., Gu, L., Li, B. & Hertz, L. Fluoxetine and all other SSRIs are 5-HT2B agonists-importance for their therapeutic effects. Curr. Neuropharmacol. 12, 365\u2013379 (2014).","journal-title":"Curr. Neuropharmacol."},{"key":"13682_CR21","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1073\/pnas.94.5.2036","volume":"94","author":"YG Ni","year":"1997","unstructured":"Ni, Y. G. & Miledi, R. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proc. Natl. Acad. Sci. 94, 2036\u20132040 (1997).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"13682_CR22","doi-asserted-by":"publisher","first-page":"e1003946","DOI":"10.1371\/journal.ppat.1003946","volume":"10","author":"SA Stanley","year":"2014","unstructured":"Stanley, S. A. et al. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog. 10, e1003946 (2014).","journal-title":"PLoS Pathog."},{"key":"13682_CR23","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.msec.2017.02.132","volume":"76","author":"M Sheikhpour","year":"2017","unstructured":"Sheikhpour, M., Golbabaie, A. & Kasaeian, A. Carbon nanotubes: A review of novel strategies for cancer diagnosis and treatment. Mater. Sci. Eng., C 76, 1289\u20131304 (2017).","journal-title":"Mater. Sci. Eng., C"},{"key":"13682_CR24","doi-asserted-by":"publisher","first-page":"412001","DOI":"10.1088\/0957-4484\/18\/41\/412001","volume":"18","author":"W Yang","year":"2007","unstructured":"Yang, W., Thordarson, P., Gooding, J. J., Ringer, S. P. & Braet, F. Carbon nanotubes for biological and biomedical applications. Nanotechnology 18, 412001 (2007).","journal-title":"Nanotechnology"},{"key":"13682_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-03031-2","volume":"11","author":"FM Kamazani","year":"2021","unstructured":"Kamazani, F. M., Siadat, S. D., Pornour, M. & Sheikhpour, M. A success targeted nano delivery to lung cancer cells with multi-walled carbon nanotubes conjugated to bromocriptine. Sci. Rep. 11, 1\u201315 (2021).","journal-title":"Sci. Rep."},{"key":"13682_CR26","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1007\/s00018-017-2532-y","volume":"74","author":"T Mocan","year":"2017","unstructured":"Mocan, T. et al. Carbon nanotubes as anti-bacterial agents. Cell. Mol. Life Sci. 74, 3467\u20133479 (2017).","journal-title":"Cell. Mol. Life Sci."},{"key":"13682_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/NSA.S260374","volume":"13","author":"M Sheikhpour","year":"2020","unstructured":"Sheikhpour, M., Arabi, M., Kasaeian, A., Rabei, A. R. & Taherian, Z. Role of nanofluids in drug delivery and biomedical technology: Methods and applications. Nanotechnol. Sci. Appl. 13, 47 (2020).","journal-title":"Nanotechnol. Sci. Appl."},{"issue":"2","key":"13682_CR28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1166\/jbn.2016.2149","volume":"12","author":"P da Silva","year":"2016","unstructured":"da Silva, P. et al. Nanotechnology-based drug delivery systems for treatment of tuberculosis: A review. J. Biomed. Nanotechnol. 12(2), 241\u2013260 (2016).","journal-title":"J. Biomed. Nanotechnol."},{"key":"13682_CR29","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.2147\/IJN.S251524","volume":"15","author":"S Zomorodbakhsh","year":"2020","unstructured":"Zomorodbakhsh, S., Abbasian, Y., Naghinejad, M. & Sheikhpour, M. The effects study of isoniazid conjugated multi-wall carbon nanotubes nanofluid on Mycobacterium tuberculosis. Int. J. Nanomed. 15, 5901 (2020).","journal-title":"Int. J. Nanomed."},{"key":"13682_CR30","doi-asserted-by":"publisher","first-page":"7063","DOI":"10.2147\/IJN.S263238","volume":"15","author":"M Sheikhpour","year":"2020","unstructured":"Sheikhpour, M. et al. The applications of carbon nanotubes in the diagnosis and treatment of lung cancer: A critical review. Int. J. Nanomed. 15, 7063 (2020).","journal-title":"Int. J. Nanomed."},{"key":"13682_CR31","first-page":"196","volume":"2","author":"SN Jain","year":"2011","unstructured":"Jain, S. N. et al. Antibiotic synergy test: Checkerboard method on multidrug resistant Pseudomonas aeruginosa. Int. Res. J. Pharm. 2, 196\u2013198 (2011).","journal-title":"Int. Res. J. Pharm."},{"key":"13682_CR32","volume-title":"Antibiotics in Laboratory Medicine","author":"V Lorian","year":"2005","unstructured":"Lorian, V. Antibiotics in Laboratory Medicine (Lippincott Williams & Wilkins, 2005)."},{"key":"13682_CR33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0924-8579(99)00154-5","volume":"14","author":"J Munoz-Bellido","year":"2000","unstructured":"Munoz-Bellido, J., Munoz-Criado, S. & Garc\u0131a-Rodr\u0131guez, J. Antimicrobial activity of psychotropic drugs: Selective serotonin reuptake inhibitors. Int. J. Antimicrob. Agents 14, 177\u2013180 (2000).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"13682_CR34","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1073\/pnas.94.5.2036","volume":"94","author":"Y Ni","year":"1997","unstructured":"Ni, Y. & Miledi, R. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proc. Natl. Acad. Sci. 94, 2036\u20132040 (1997).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"13682_CR35","doi-asserted-by":"publisher","first-page":"13881","DOI":"10.1073\/pnas.2235848100","volume":"100","author":"R Rawat","year":"2003","unstructured":"Rawat, R., Whitty, A. & Tonge, P. J. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance. Proc. Natl. Acad. Sci. 100, 13881\u201313886 (2003).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"13682_CR36","doi-asserted-by":"publisher","first-page":"17200","DOI":"10.1074\/jbc.RA118.005405","volume":"293","author":"B V\u00f6geli","year":"2018","unstructured":"V\u00f6geli, B. et al. InhA, the enoyl-thioester reductase from Mycobacterium tuberculosis forms a covalent adduct during catalysis. J. Biol. Chem. 293, 17200\u201317207 (2018).","journal-title":"J. Biol. Chem."},{"key":"13682_CR37","first-page":"107","volume":"8","author":"MMK Kumar","year":"2018","unstructured":"Kumar, M. M. K., Madhavi, K., Mohan, T., Nagasree, K. P. & Sangeeta, G. Novel synthetic analogues of Fluoxetine as potent and selective anti-TB agents. J. Appl. Pharm. Sci. 8, 107\u2013115 (2018).","journal-title":"J. Appl. Pharm. Sci."},{"key":"13682_CR38","doi-asserted-by":"publisher","first-page":"015101","DOI":"10.1088\/0957-4484\/19\/01\/015101","volume":"19","author":"MG Schrlau","year":"2007","unstructured":"Schrlau, M. G., Falls, E. M., Ziober, B. L. & Bau, H. H. Carbon nanopipettes for cell probes and intracellular injection. Nanotechnology 19, 015101 (2007).","journal-title":"Nanotechnology"},{"key":"13682_CR39","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1128\/iai.65.11.4843-4849.1997","volume":"65","author":"CH Ladel","year":"1997","unstructured":"Ladel, C. H. et al. Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect. Immun. 65, 4843\u20134849 (1997).","journal-title":"Infect. Immun."},{"key":"13682_CR40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jconrel.2017.03.026","volume":"253","author":"M Sheikhpour","year":"2017","unstructured":"Sheikhpour, M., Barani, L. & Kasaeian, A. Biomimetics in drug delivery systems: A critical review. J. Control. Release 253, 97\u2013109 (2017).","journal-title":"J. Control. Release"},{"issue":"10","key":"13682_CR41","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1166\/jbn.2021.3169","volume":"17","author":"W Ma","year":"2021","unstructured":"Ma, W. et al. Efficacy of dual-targeting combined anti-tuberculosis drug delivery system in the treatment of tuberculous meningitis. J. Biomed. Nanotechnol. 17(10), 2034\u20132042 (2021).","journal-title":"J. Biomed. Nanotechnol."},{"issue":"8","key":"13682_CR42","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3390\/antibiotics10080908","volume":"10","author":"MKN Mazlan","year":"2021","unstructured":"Mazlan, M. K. N. et al. Antituberculosis targeted drug delivery as a potential future treatment approach. Antibiotics 10(8), 908 (2021).","journal-title":"Antibiotics"},{"key":"13682_CR43","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jconrel.2020.08.033","volume":"328","author":"M Mohammadi","year":"2020","unstructured":"Mohammadi, M., Arabi, L. & Alibolandi, M. Doxorubicin-loaded composite nanogels for cancer treatment. J. Control. Release 328, 171\u2013191 (2020).","journal-title":"J. Control. Release"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13682-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13682-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13682-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T04:14:27Z","timestamp":1669349667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13682-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["13682"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-13682-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]},"assertion":[{"value":"28 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9591"}}